Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. - Wikidata - awgldk - TriplyDB

Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration.

Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration.

http://www.wikidata.org/entity/Q44249268

about

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration Ranibizumab and bevacizumab for neovascular age-related macular degeneration Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration Myopic choroidal neovascularisation: current concepts and update on clinical management The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials Cost-effectiveness of treatment of diabetic macular edema.Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials.Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration.Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.Systemic safety of anti-VEGF drugs: a commentary.Review of therapeutic advances in diabetic retinopathy.Ranibizumab and risk of hospitalisation for ischaemic stroke and myocardial infarction in patients with age-related macular degeneration: a self-controlled case-series analysis.The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch O Current treatments in diabetic macular oedema: systematic review and meta-analysis Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab.Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.Long-lasting effects of anti-VEGF/photodynamic combination therapy in the treatment of exudative age-related macular degeneration: a retrospective chart review.Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy.A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications.Liposomal hypocrellin B as a potential photosensitizer for age-related macular degeneration: pharmacokinetics, photodynamic efficacy, and skin phototoxicity in vivo.Management of neovascular age-related macular degeneration in clinical practice: initiation, maintenance, and discontinuation of therapy.Age-Related Macular Degeneration and Incident Stroke: A Systematic Review and Meta-Analysis Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines Comparison of systemic adverse events associated with intravitreal anti-VEGF injection: ranibizumab versus bevacizumab Ten-year incidence of age-related macular degeneration according to diabetic retinopathy classification among medicare beneficiaries Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls.Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results.Treatments for macular oedema following central retinal vein occlusion: systematic review.Ranibizumab for age-related macular degeneration.Geriatric vision loss due to cataracts, macular degeneration, and glaucoma.

P2860

Q21090878-EAA99323-A5FC-4AD1-B3AB-5E459C15AA3E Q22305863-5CD5E5CA-3094-4139-9B2F-6C8523BFEFFE Q24193614-B8E2C644-0181-441E-B2C6-061397520706 Q24616209-42D434C2-5D47-4593-8B7B-DB519878A10C Q26771522-BFF2AF3F-FB10-46D3-A713-F42615023D2A Q26852289-2629695B-0E4D-496D-AFC6-E0F4A4BE5A3F Q26865884-921BC1B2-6665-4606-8509-6E6461BCFD9D Q27013836-05B2B1E8-3F45-4EDE-80B8-1234DEE9130B Q28049700-ADD94E9F-DFBE-41C4-A4FE-2DC1F141E20C Q33606611-D7A01365-BE57-44B7-9B1B-3C56245A9A8B Q33830753-16EC34AE-EBFB-4C96-A4A8-C7450ABA159C Q33995880-FA413C8C-0D25-4EAE-9893-E062559747C7 Q34115840-78D2E18D-A2A6-41A2-9F76-57FAF9830EC7 Q34158108-784C2880-EC46-46E7-9257-F429666B0186 Q34444212-5841F87C-3B4F-49D3-B939-1BDC0EDFA6CB Q34452811-DCD7AD9A-A6F5-486D-9AC2-CE96579AC0A4 Q34475449-6B3F0E89-58F3-4A99-AEC1-863A6B7D7800 Q34567356-99061712-3E10-4950-8AE8-8B172FD72051 Q34588174-F1C2F434-23D7-401D-AC75-2CE04F757E46 Q34606190-88075AC9-E298-4498-B542-E02F49A38FBA Q34627103-D05CC126-B94C-4231-88C4-BFECF4090B7F Q34740219-6DDBC6DB-3A05-4B98-AFA2-8F7E652DF695 Q34742560-619FFC0E-825F-4960-A26D-F3AA9455FCBD Q35016867-9F3DCB49-0599-4616-83A7-FB3E16FC0A71 Q35188790-85FC78BC-A6B4-49FC-B819-E7E25DA22070 Q35226722-45BACD18-5EE8-40F8-A362-CC726599F512 Q35582389-FA98AC57-7F5A-4A3E-8410-707264DEB826 Q35585178-5CBDD412-CF62-449A-B758-0DCBEC723655 Q35845015-1E471E36-270D-4203-98E4-117434FDCE24 Q36075546-A804EA9E-4180-40C6-B025-4F45A4E82A73 Q36374429-639A041D-B6E7-47A1-AA7A-F661AAEF5FD2 Q36473024-1A20CAD0-95F0-4ABA-80BF-F2F62725D7C6 Q36791356-7262DB08-7FBF-42CF-BEA1-51A43439EAE2 Q36906875-8BEC7255-3575-499C-BE71-523D61E29409 Q37129912-5B30C002-58C6-4DBD-86A6-5F8E30B28288 Q37455178-17543532-023C-4962-800B-AD974E5B8383 Q37474648-79536745-49EE-4D71-907C-6A820C69274C Q37590692-18C156E2-287D-4762-8D7D-CF1FFD4F5DA1 Q37981760-15DFAC7D-400E-4DA2-94D4-6577EE675114 Q38002373-CDA92610-E490-4589-9D8E-503B816DF180

P2860

Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration.

http://www.wikidata.org/entity/Q44249268

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Risks of mortality, myocardial ...... -related macular degeneration.

@en

Risks of mortality, myocardial ...... -related macular degeneration.

@nl

type

label

Risks of mortality, myocardial ...... -related macular degeneration.

@en

Risks of mortality, myocardial ...... -related macular degeneration.

@nl

prefLabel

Risks of mortality, myocardial ...... -related macular degeneration.

@en

Risks of mortality, myocardial ...... -related macular degeneration.

@nl

P1433

Q44249268-A49C11F5-E2E6-4EAF-80C1-C9F3BD1B4723

P1476

Q44249268-01A94EAE-CA77-4A24-9815-E6174218224A

P2093

Q44249268-4A8D7782-611E-4A2C-A134-2722DC2AE588

Q44249268-54811CDB-5B57-4E20-8953-60225CFB85BC

Q44249268-6A04505C-9A38-41BB-AAA6-AA8C9D0EF503

Q44249268-86F75332-F04B-45CB-BE21-C1DF6C2150AC

P304

Q44249268-14933BF7-4AE7-4540-A812-E04C16F1820E

P31

Q44249268-93EC7789-1503-4580-B6FC-1559D0DE998C

P356

Q44249268-9AD8A3E1-10BF-4733-8DDC-0F7797C10673

P407

Q44249268-30DBFF12-5437-4E69-A94F-2A016AE4816C

P433

Q44249268-4E5D1F62-F35D-4595-8C1A-6B0310060AF3

P478

Q44249268-0958B22D-52A3-409E-A4F8-1C555EE0966C

P577

Q44249268-808B9866-82C4-4160-A63E-35190D583A85

P698

Q44249268-4B36DD26-AB69-443A-81BA-D5FE07E7CA82

P921

Q44249268-A0B6EE3C-CE3A-4C51-9F3F-0D8592A16027

P356

ARCHOPHTHALMOL.2010.223

P1433

JAMA Ophthalmology

P1476

Risks of mortality, myocardial ...... -related macular degeneration.

@en

P2093

Bradley G Hammill

http://www.w3.org/2001/XMLSchema#string

Kevin A Schulman

http://www.w3.org/2001/XMLSchema#string

Lesley H Curtis

http://www.w3.org/2001/XMLSchema#string

Scott W Cousins

http://www.w3.org/2001/XMLSchema#string

P304

1273-1279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHOPHTHALMOL.2010.223

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20937996

http://www.w3.org/2001/XMLSchema#string

P921